Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India

References

• SungH, FerlayJ, SiegelRL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/CAAC.2166033538338
   PubMed Web of Science ®Google Scholar
• MalviaS, BagadiSA, DubeyUS, SaxenaS. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289–295. doi:10.1111/AJCO.1266128181405
   PubMed Web of Science ®Google Scholar
• DovalDC, RadhakrishnaS, TripathiRet al. A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery. Sci Rep. 2020;10(1). doi:10.1038/S41598-020-62618-3
   Web of Science ®Google Scholar
• LurieRH, AndersonBO, AbrahamJ, et al. NCCN guidelines version 5.2020 breast cancer; 2020.
   Google Scholar
• Standard treatment guidelines oncology. Ministry of health & family welfare Government of India 2.
   Google Scholar
• Del MastroL, MansuttiM, BisagniG, et al. Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: a randomized, Phase III study of Gruppo Italiano Mammella (GIM). Am Soc Clin Oncol. 2019;37(15_suppl):504. doi:10.1200/JCO.2019.37.15_SUPPL.504
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352. doi:10.1016/S0140-6736(15)61074-126211827
   PubMed Web of Science ®Google Scholar
• BursteinHJ, GriggsJJ, PrestrudAA, TeminS. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010;6(5):243–246. doi:10.1200/JOP.00008221197188
   PubMedGoogle Scholar
• AgarwalG, RamakantP. Breast cancer care in India: the current scenario and the challenges for the future. Breast Care. 2008;3(1):21. doi:10.1159/000115288
   PubMed Web of Science ®Google Scholar
• FariasAJ, HansenRN, ZeliadtSB, OrnelasIJ, LiCI, ThompsonB. The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. Am J Clin Oncol. 2018;41(7):708–715. doi:10.1097/COC.000000000000035127893470
   PubMed Web of Science ®Google Scholar
• SasseAD, Sasse EC. Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer. Rev Assoc Med Bras. 2009;55(5):535–540. doi:10.1590/S0104-4230200900050001519918652
   PubMed Web of Science ®Google Scholar
• LockerGY, ManselR, CellaD, DobrezD, SorensenS, GandhiSK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (“Arimidex”, Tamoxifen Alone. Breast Cancer Res Treat. 2007;106(2):229–238. doi:10.1007/S10549-006-9483-617245540
   PubMed Web of Science ®Google Scholar
• LuxMP, WöckelA, BenedictA, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie. 2010;33(4):155–166. doi:10.1159/00028623320389141
   PubMedGoogle Scholar
• ManselR, LockerG, FallowfieldL, BenedictA, JonesD. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial. Br J Cancer. 2007;97(2):152–161. doi:10.1038/sj.bjc.660380417622238
   PubMed Web of Science ®Google Scholar
• MoeremansK, AnnemansL. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer. 2006;16(Suppl 2):576–578. doi:10.1111/J.1525-1438.2006.00699.X17010076
   PubMedGoogle Scholar
• FonsecaM, AraújoGTB, SaadED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras. 2009;55(4):410–415. doi:10.1590/s0104-4230200900040001519750307
   PubMed Web of Science ®Google Scholar
• DjalalovS, BecaJ, AmirE, KrahnM, TrudeauME, HochJS. Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada. Curr Oncol. 2015;22(2):84–96. doi:10.3747/CO.22.212025908907
   PubMed Web of Science ®Google Scholar
• YeM, LuJ, YangF, WuB. Economic evaluation of letrozole for early breast cancer in a health resource-limited setting. Biomed Res Int. 2018;2018:1–8. doi:10.1155/2018/9282646
   Web of Science ®Google Scholar
• DeleaTE, KarnonJ, SofryginO, ThomasSK, PapoNL, BarghoutV. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007;7(8):608–618. doi:10.3816/CBC.2007.N.01817592673
   PubMed Web of Science ®Google Scholar
• DeleaTE, El-OuagariK, KarnonJ, SofryginO. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008;108(3):375–387. doi:10.1007/S10549-007-9607-717653859
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-015894097
   PubMed Web of Science ®Google Scholar
• PrinjaS, ChauhanAS, AngellB, GuptaI, JanS. A systematic review of the state of economic evaluation for health care in India. Appl Health Econ Health Policy. 2015;13(6):595–613. doi:10.1007/S40258-015-0201-626449485
   PubMed Web of Science ®Google Scholar
• Department of Health Research, Ministry of Health & Family Welfare. Health technology assessment in India a manual; 2018. Available from: https://dhr.gov.in/. Accessed July31, 2021.
   Google Scholar
• Tan-Torres EdejerT. Making choices in health: WHO guide to cost-effectiveness analysis; 2003. Available from: https://www.who.int/choice/publications/p_2003_generalised_cea.pdf. Accessed July31, 2021.
   Google Scholar
• ManoharanN, NairO, ShuklaNK, RathGK. Descriptive epidemiology of female breast cancer in Delhi, India. Asian Pac J Cancer Prev. 2017;18(4):1015–1018. doi:10.22034/APJCP.2017.18.4.101528545200
   PubMedGoogle Scholar
• RocchiA, VermaS. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer. 2006;14(9):917–927. doi:10.1007/s00520-006-0035-816596419
   PubMed Web of Science ®Google Scholar
• ShihV, ChanA, XieF, KoY. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore. Value Heal Reg Issues. 2012;1(1):46–53. doi:10.1016/J.VHRI.2012.03.013
   Google Scholar
• AmirE, SerugaB, NiraulaS, CarlssonL, OcañaA. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–1309. doi:10.1093/JNCI/DJR24221743022
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization. Available from: https://www.who.int/choice/publications/p_2003_generalised_cea.pdf. Accessed October10, 2021.
   Google Scholar
• HusereauD, DrummondM, PetrouS. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi:10.1016/J.JVAL.2013.02.00223538175
   PubMed Web of Science ®Google Scholar
• ICMR. Consensous document for management of breast cancer; 2016. Available from: http://cancerindia.org.in/wp-content/uploads/2017/11/Breast_Cancer.pdf. Accessed October29, 2021.
   Google Scholar
• SmithI, YardleyD, BurrisHet al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III Femara versus Anastrozole Clinical Evaluation (FACE) trial. J Clin Oncol. 2017;35(10):1041–1048. doi:10.1200/JCO.2016.69.287128113032
   PubMed Web of Science ®Google Scholar
• KhanUT, WalkerAJ, BaigS, CardTR, KirwanCC, GraingeMJ. Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer. 2017;17(1):1–13. doi:10.1186/S12885-017-3719-128049525
   PubMed Web of Science ®Google Scholar
• FisherB, CostantinoJP, RedmondCK, FisherER, WickerhamDL, CroninWM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–537. doi:10.1093/jnci/86.7.5278133536
   PubMed Web of Science ®Google Scholar
• HowellA, CuzickJ, BaumMet al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–62. doi:10.1016/S0140-6736(04)17666-615639680
   PubMed Web of Science ®Google Scholar
• SRS bulletin sample registration system registrar general, India; 2016. Available from: http://www.censusindia.gov.in. Accessed July31, 2021.
   Google Scholar
• TongsiriS, CairnsJ. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011;14(8):1142–1145. doi:10.1016/J.JVAL.2011.06.00522152185
   PubMed Web of Science ®Google Scholar
• PeasgoodT, WardSE, BrazierJ. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):553–566. doi:10.1586/ERP.10.6520950071
   PubMed Web of Science ®Google Scholar
• PeasgoodT, HerrmannK, KanisJA, BrazierJE. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853–868. doi:10.1007/S00198-009-0844-Y19271098
   PubMed Web of Science ®Google Scholar
• MittmannN, TrakasK, RisebroughN, LiuBA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369–376. doi:10.2165/00019053-199915040-0000410537955
   PubMed Web of Science ®Google Scholar
• GoldMR, FranksP, McCoyKI, FrybackDG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778–792. doi:10.1097/00005650-199806000-000029630120
   PubMed Web of Science ®Google Scholar
• AraR, BrazierJ. Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods. Med Care. 2012;50(5):452–459. doi:10.1097/MLR.0B013E318234A04A22002647
   PubMed Web of Science ®Google Scholar
• Implementation MoSaP. Health in India: NSS 71st Round; 2014. Available from: http://mospi.nic.in/. Accessed October29, 2021.
   Google Scholar
• Tamil Nadu Medical Services Corporation Limited. Essential drug 1 year rate contract details from March 2019; 2019. Available from: https://tnmsc.tn.gov.in/user_pages/drugtender.php?drugcat=T18028. Accessed July31, 2021.
   Google Scholar
• WhiteRH, ZhouH, RomanoPS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med. 1998;158(9):1005–1010. doi:10.1001/ARCHINTE.158.9.10059588434
   PubMedGoogle Scholar
• HansenRN, PhamAT, BoingEAet al. Reduced length of stay and hospitalization costs among inpatient hysterectomy patients with postoperative pain management including IV versus oral Acetaminophen. PLoS One. 2018;13(9). doi:10.1371/JOURNAL.PONE.0203746
   Web of Science ®Google Scholar
• ColzaniE, ClementsM, JohanssonALV. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer. 2016;115(11):1400–1407. doi:10.1038/BJC.2016.31427701383
   PubMed Web of Science ®Google Scholar
• GoldhirschA, GlickJH, GelberRD, CoatesAS, ThürlimannB, SennHJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569–1583. doi:10.1093/ANNONC/MDI32616148022
   PubMed Web of Science ®Google Scholar
• MunshiA, GuptaS, YarnoldJ. Guidelines for locoregional therapy in primary breast cancer in developing countries: the results of an expert panel at the 8th Annual Women′s Cancer Initiative - Tata Memorial Hospital (WCI-TMH) Conference. Indian J Med Paediatr Oncol. 2012;33(2):112–122. doi:10.4103/0971-5851.9974822988354
   PubMedGoogle Scholar
• PassarelloK, KurianS, VillanuevaV. Endometrial cancer: an overview of pathophysiology, management, and care. Semin Oncol Nurs. 2019;35(2):157–165. doi:10.1016/J.SONCN.2019.02.00230867105
   PubMed Web of Science ®Google Scholar
• PrinjaS, BrarS, SinghMP, et al. Process evaluation of health system costing – experience from CHSI study in India. PLoS One. 2020;15(5):e0232873. doi:10.1371/JOURNAL.PONE.023287332401763
   PubMed Web of Science ®Google Scholar
• PrinjaS, SinghMP, GuinnessL, RajsekarK, BhargavaB. Establishing reference costs for the health benefit packages under universal health coverage in India: cost of health services in India (CHSI) protocol. BMJ Open. 2020;10(7):e035170. doi:10.1136/BMJOPEN-2019-035170
   PubMed Web of Science ®Google Scholar
• National Health Authority, Government of India. Health benefit package 2.0; 2020. Available from: https://pmjay.gov.in/sites/default/files/2021-06/National-Master-for-Website_0.pdf. Accessed July31, 2021.
   Google Scholar
• ChauhanAS, PrinjaS, GhoshalS, VermaR. Economic burden of head and neck cancer treatment in North India. Asian Pac J Cancer Prev. 2019;20(2):403. doi:10.31557/APJCP.2019.20.2.40330803199
   PubMedGoogle Scholar
• Ministry of Health & Family Welfare, Government of India. Central government health scheme; 2021. Available from: https://cghs.gov.in/index.php. Accessed July31, 2021.
   Google Scholar
• Dr Lal PathLabs. Diagnostics lab test A-Z list | Medical Tests -Dr Lal PathLabs; 2018. Available from: https://www.lalpathlabs.com/tests-list.aspx. Accessed July31, 2021.
   Google Scholar
• Practo. Available from: https://www.practo.com/?utm_source=google&utm_medium=cpc&utm_campaign=brand-search-practo-consult&sem=true&gclid=Cj0KCQjw6ZOIBhDdARIsAMf8YyFa2sdHZyt7Wwf8Dz7KoVqQQaZJeQy2ra5UcqiorhxLgVwFEFJJfocaAiJ5EALw_wcB. Accessed July31, 2021.
   Google Scholar
• KarnonJ, DeleaT, BarghoutV. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. 2008;9(2):171–183. doi:10.1007/S10198-007-0058-117602251
   PubMed Web of Science ®Google Scholar
• LazzaroC. Cost-utility analysis of anastrozole versus tamoxifen for adjuvant treatment in postmenopausal women with early breast cancer. PharmacoEconomics. 2007;9:31–43. doi:10.1007/BF03320568
   Google Scholar
• SkedgelC, RaysonD, DewarR, YounisT. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast. 2007;16(3):252–261. doi:10.1016/J.BREAST.2006.12.00217207623
   PubMed Web of Science ®Google Scholar
• GamboaO, DíazS, ChicaízaL, GarcíaM. Análisis de costo-efectividad en Colombia de anastrazol Vs. tamoxifeno como terapia inicial en mujeres con cáncer temprano de mama y receptor hormonal positivo [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer]. Biomedica. 2010;30(1):46–55. Spanish. doi:10.7705/biomedica.v30i1.15220890549
   PubMed Web of Science ®Google Scholar
• MahdiH, HanX, MoultonL, VargasR. Trends in survival of patients with uterine serous carcinoma from 1988 to 2011: a population-based study. Int J Gynecol Cancer. 2017;27(6):1155–1164. doi:10.1097/IGC.000000000000100728562471
   PubMed Web of Science ®Google Scholar
• ParkashR, WeeV, GardnerMJ, et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol. 2007;23(6):457. doi:10.1016/S0828-282X(07)70784-517487290
   PubMed Web of Science ®Google Scholar
• Consolidated report of hospital based cancer registries: 2012–2014. Available from: https://www.ncdirindia.org/All_Reports/HBCR_REPORT_2012_2014/index.htm. Accessed July31, 2021.
   Google Scholar
• MansourS, AlotaibiG, WuC, McMurtryMS. Trends in admission rates and in-hospital stay for venous thromboembolism. Thromb Res. 2017;156:149–154. doi:10.1016/J.THROMRES.2017.06.01228646726
   PubMed Web of Science ®Google Scholar
• ReganMM, NevenP, Giobbie-HurderA. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011;12(12):1101–1108. doi:10.1016/S1470-2045(11)70270-422018631
   PubMed Web of Science ®Google Scholar
• Department of Community Medicine & School of Public Health, PGIMER Chandigarh. National health system cost database for India. PGISPH.IN; 2021. Available from: https://www.healtheconomics.pgisph.in/costing_web/. Accessed July31, 2021.
   Google Scholar